Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide-purged marrow for acute lymphoblastic leukemia

Med Pediatr Oncol. 1991;19(3):160-4. doi: 10.1002/mpo.2950190303.

Abstract

Ten patients age 13-52 years with acute lymphoblastic leukemia (ALL) in first complete remission (CR) (1), second CR (6), or relapse (3) were treated with cyclophosphamide 50 mg/kg daily x 4 and total body irradiation 3 Gy daily x 4 followed by infusion of autologous marrow purged with 4-hydroperoxycyclophosphamide (4-HC) at 100-120 micrograms/ml. The patients transplanted in relapse also received 2 mg vincristine and corticosteroids. All marrows were harvested while patients were in CR. The nucleated marrow cell dose was 3.5 +/- 0.7 x 10(8)/kg, and the CFU-GM content of the transplant was 0.4 +/- 0.5 x 10(3)/kg after purging with 4-HC. Median time from transplantation is 48 months. The neutrophil count (ANC) exceeded 1.0 x 10(9)/L at a median of 26 days and platelets exceeded 50 x 10(9)/L at 34 days. All patients were in remission after transplantation (ABMT). Five patients relapsed 2-9 months after ABMT (actuarial rate 60%). Three patients are alive and in CR at 17+, 43+, and 54+ months after ABMT. Purging marrow with 4-HC did not adversely affect engraftment, but it is not clear if the high relapse rate was due to incomplete ex vivo purging or inadequacy of the conditioning regimen.

Publication types

  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Adolescent
  • Adult
  • Bone Marrow / drug effects*
  • Bone Marrow / pathology
  • Bone Marrow Transplantation* / methods
  • Cyclophosphamide / analogs & derivatives*
  • Cyclophosphamide / therapeutic use
  • Female
  • Follow-Up Studies
  • Granulocytes / pathology
  • Humans
  • Macrophages / pathology
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery*
  • Remission Induction
  • Stem Cells / pathology
  • Survival Rate
  • Whole-Body Irradiation

Substances

  • Cyclophosphamide
  • perfosfamide